The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
Precision will be at this year’s Meeting on the Med, April 9-11, 2023, in Rome, Italy. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
You can register for Meeting on the Med below:
Precision will be at this year’s Gene Therapy for Rare Disorders on March 26-29, 2024, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
—
Plenary Speaking Position: What to Look Forward to for Gene Therapy in 2024
Precision | March 27, 2024, 8:30 – 9AM ET
Speakers:
Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Precision | March 28, 2024, 11:15AM – 12:15PM ET
Precision’s Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series.
“Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types.” (subscription required):
As clinical trial protocols have become more complex in recent years, institutions are facing new challenges in keeping up with the advancements. In this Q&A, Precision’s Sofia Baig, President of Clinical Solutions, discusses the challenges these institutions are facing, how sites can keep pace with new technologies, and improving efficiency in early and later phase research.
The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside. Precision’s Deb Phippard surveys the landscape in MedCity News.
Last year’s FDA draft guidance for the research of psychedelic drugs offered a pathway for research for the biopharmaceutical industry. In The Hill, Precision’s Robert Bauer discusses the challenges to ultimate approval by the FDA.
Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by single gene mutations. AAV-based therapeutics have been the most successful in vivo gene therapies for patients with central nervous system disorders. Precision’s Deb Phippard identifies challenges to their development with assessing, minimizing and mitigating immunogenicity.
Despite a potentially record-breaking year for the cell and gene therapy industry, certain challenges remain. Precision’s Anshul Mangal identifies ways innovation can overcome hurdles that may ultimately stand in the way of broader accessibility.
Precision will be at this year’s Advanced Therapies Week, January 16 – 19, in Miami, FL. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for advanced therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
Connect with our Advanced Therapy experts
You can register for Advanced Therapies Week below:
Recent AI applications rely heavily on predictive AI, which harnesses historical data to make predictions and recommendations for the future. But what is really propelling the industry forward is generative AI, which uses models or algorithms to create various types of content using learned patterns based on the data on which it was trained.
SVP/Chief Architect Tobias Guennel outlines how generative AI will speed up clinical trial execution as sponsors integrate AI-enabled technologies into their day-to-day workflows.